Across healthy donors, SRSF2-WT AML, and SRSF2-mutant AML, the mutant group showed higher DSS to CHK1 inhibitors, prexasertib (Figure 2C) and PF-00477736 (Figure 2D), and to the WEE1 inhibitor adavosertib (Figure 2E). The gene discussed is CHEK1; the disease is acute myeloid leukemia.